Price (delayed)
$147.15
Market cap
$10.52B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.81
Enterprise value
$11.05B
Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including
There are no recent dividends present for BHVN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.